New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or ...

Biogen stock rises as Novo Nordisk's Alzheimer's trials disappoint, spotlighting Leqembi's role and a new immunology ...

Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around ...

A 19-year-old who was diagnosed with a rare form of motor neurone disease (MND) in August has said it is "disgusting" that ...

Biogen Inc. struck a deal with a biotech startup to research immune disorder treatments, part of an expansion of its ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...